In line with this hypothesis, we investigated, in a large cohort of 309 breast carcinoma from whom complete follow-up data were collected, the potential association of the gene deletion of GSTM1 and GSTT1 enzymes with tumour clinic-pathologic characteristics and with the increased risk of relapse and death from breast carcinoma. Here, GSTM1 is linked to breast carcinoma.